New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis

被引:7
|
作者
Li, Xin
Zhou, Jianbo
Wang, Xue
Li, Chunxi
Ma, Zifan
Wan, Qiaoling
Peng, Fu
机构
[1] Sichuan Univ, West China Sch Pharm, Dept Pharmacol, Key Lab Drug Targeting & Drug Delivery Syst,Educ, Chengdu 610041, Peoples R China
[2] Sichuan Univ, Sichuan Res Ctr Drug Precis Ind Technol, West China Sch Pharm, Chengdu 610041, Peoples R China
基金
中国国家自然科学基金;
关键词
Angiogenesis; Tumor; Antiangiogenic drugs; Clinical treatment; Signaling pathway; CELL LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; DIFFERENTIATED THYROID-CANCER; EMODIN INHIBITS ANGIOGENESIS; TUBEROUS SCLEROSIS COMPLEX; RECEPTOR TYROSINE KINASES; VIVO ANTITUMOR-ACTIVITY; NOGO-B RECEPTOR; DOUBLE-BLIND;
D O I
10.1016/j.biopha.2023.114806
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In 1971, Folkman proposed that tumors could be limited to very small sizes by blocking angiogenesis. Angiogenesis is the generation of new blood vessels from pre-existing vessels, considered to be one of the important processes in tumor growth and metastasis. Angiogenesis is a complex process regulated by various factors and involves many secreted factors and signaling pathways. Angiogenesis is important in the transport of oxygen and nutrients to the tumor during tumor development. Therefore, inhibition of angiogenesis has become an important strategy in the clinical management of many solid tumors. Combination therapies of angiogenesis inhibitors with radiotherapy and chemotherapy are often used in clinical practice. In this article, we will review common targets against angiogenesis, the most common and up-to-date anti-angiogenic drugs and clinical treatments in recent years, including active ingredients from chemical and herbal medicines.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Advances in the Treatment of Metastatic Melanoma: New Immunomodulatory Agents
    Sznol, Mario
    SEMINARS IN ONCOLOGY, 2012, 39 (02) : 192 - 203
  • [32] The pipeline of new anticancer agents for breast cancer treatment in 2003
    Awada, A
    Cardoso, F
    Atalay, G
    Giuliani, R
    Mano, M
    Piccart, M
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 48 (01) : 45 - 63
  • [33] Clinical evaluation of anticancer agents with tumor tissue-derived culture cells
    Hoshi, Hirotaka
    Tamura, Hirosumi
    Imai, Jun-ichi
    Watanabe, Shinya
    CANCER SCIENCE, 2018, 109 : 1150 - 1150
  • [34] New perspectives in clinical oncology from angiogenesis research
    Folkman, J
    EUROPEAN JOURNAL OF CANCER, 1996, 32A (14) : 2534 - 2539
  • [35] The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma
    Cheng-Yuan Gu
    Bo Dai
    Yao Zhu
    Guo-Wen Lin
    Hong-Kai Wang
    Ding-Wei Ye
    Xiao-Jian Qin
    Molecular Medicine, 2022, 28
  • [36] The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma
    Gu, Cheng-Yuan
    Dai, Bo
    Zhu, Yao
    Lin, Guo-Wen
    Wang, Hong-Kai
    Ye, Ding-Wei
    Qin, Xiao-Jian
    MOLECULAR MEDICINE, 2022, 28 (01)
  • [37] Novel immunotherapies for psoriasis: Clinical research delivers new hope for patients and scientific advances
    Gottlieb, AB
    JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, 2004, 9 (01) : 79 - 83
  • [38] Rile of Macrophage Polarization in Tumor Angiogenesis and Vessel Normalization: Implications for New Anticancer Therapies
    Chen, Peiwen
    Bonaldo, Paolo
    INTERNATIONAL REVIEW OF CELL AND MOLECULAR BIOLOGY, VOL 301, 2013, 301 : 1 - 35
  • [39] THE ADVANCES IN THE RESEARCH OF NEW EXPERIMENTAL TUMOR STRAIN IN CHINA
    Qian Zhenchao Dalian Medical College
    大连医科大学学报, 1987, (02) : 112 - 133
  • [40] Novel agents and incremental advances in the treatment of head and neck cancer
    Khuri, FR
    Jain, SR
    SEMINARS IN ONCOLOGY, 2004, 31 (02) : 3 - 10